UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

Annals of oncology, 2013-05, Vol.24 (5), p.1238-1244

2013

Volltextzugriff (PDF)

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Annals of oncology, 2013-12, Vol.24 (12), p.2972-2977

2013

Volltextzugriff (PDF)

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Annals of oncology, 2015-04, Vol.26 (4), p.743-749

2015

Volltextzugriff (PDF)

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt319-djt319

2014

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Volltextzugriff (PDF)

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Cancer treatment reviews, 2016-02, Vol.43, p.67-73

2016

Volltextzugriff (PDF)

Immunotherapy in prostate cancer: review of the current evidence

Clinical & translational oncology, 2015-05, Vol.17 (5), p.339-357

2015

Volltextzugriff (PDF)

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

European journal of cancer (1990), 2015-09, Vol.51, p.S183-S183

2015

Volltextzugriff (PDF)

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S176-S177

2015

Volltextzugriff (PDF)

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

European journal of cancer (1990), 2015-09, Vol.51, p.S172-S173

2015

Volltextzugriff (PDF)

Spin and bias: the tip of the iceberg

Annals of oncology, 2013-07, Vol.24 (7), p.1949-1950

2013

Volltextzugriff (PDF)

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S480-S481

2018

Volltextzugriff (PDF)

LBA51 - CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30, p.v885-v885

2019

Volltextzugriff (PDF)

CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30, p.v885

2019

Volltextzugriff (PDF)

LBA51CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: a Meta-Analysis

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

1386O_PRRISK OF INCREMENTAL TOXICITIES AND ASSOCIATED COSTS OF NEW ANTICANCER DRUGS: A META-ANALYSIS

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Volltextzugriff (PDF)

Spin and bias: the tip of the iceberg

Annals of oncology, 2013-07, Vol.24 (7), p.1949-1949

Berger, V.W.

2013

Volltextzugriff (PDF)

Author Financial Conflicts of Interest (Fcois) in Clinical Practice Guidelines (Cpgs) for Systemic Anti-Cancer Drugs

Annals of oncology, 2014-09, Vol.25, p.iv486

2014

Volltextzugriff (PDF)

1385OAUTHOR FINANCIAL CONFLICTS OF INTEREST (FCOIS) IN CLINICAL PRACTICE GUIDELINES (CPGS) FOR SYSTEMIC ANTI-CANCER DRUGS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv486-iv486

2014

Volltextzugriff (PDF)

Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)

Annals of oncology, 2016-10, Vol.27, p.vi249-vi249

2016

Volltextzugriff (PDF)

Abstract P6-06-12: Prognostic significance of pretreatment neutrophil/-lymphocyte ratio in breast cancer: A meta-analysis

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-12

2013

Volltextzugriff (PDF)

Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors

Annals of oncology, 2012-09, Vol.23, p.ix91

2012

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657

2014

Volltextzugriff (PDF)

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2014-06, Vol.106 (6), p.dju124-dju124

2014

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Oncology
(30)
Humans
(29)
Biological And Medical Sciences
(10)
Hematology, Oncology And Palliative Medicine
(10)
Male
(10)
Medical Sciences
(10)
Tumors
(10)
Aged
(8)
Female
(8)
Middle Aged
(8)
Multiple Tumors. Solid Tumors. Tumors In Childhood
(8)
Aged, 80 And Over
(7)
Antineoplastic Agents - Therapeutic Use
(7)
Breast Cancer
(7)
Prostate Cancer
(7)
Antineoplastic Agents - Adverse Effects
(6)
Disease-Free Survival
(6)
Neoplasms - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Immunotherapy in prostate cancer: review of the current evidence

1229 Industry-Sponsored Posters at Major Oncology Conferences: Science or Marketing?

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs

Spin and bias: the tip of the iceberg

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC

LBA51 - CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

LBA51CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: a Meta-Analysis

1386O_PRRISK OF INCREMENTAL TOXICITIES AND ASSOCIATED COSTS OF NEW ANTICANCER DRUGS: A META-ANALYSIS

Spin and bias: the tip of the iceberg

Author Financial Conflicts of Interest (Fcois) in Clinical Practice Guidelines (Cpgs) for Systemic Anti-Cancer Drugs

1385OAUTHOR FINANCIAL CONFLICTS OF INTEREST (FCOIS) IN CLINICAL PRACTICE GUIDELINES (CPGS) FOR SYSTEMIC ANTI-CANCER DRUGS

Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): A phase II trial in men with metastatic castrate resistant prostate cancer (mCRPC)

Abstract P6-06-12: Prognostic significance of pretreatment neutrophil/-lymphocyte ratio in breast cancer: A meta-analysis

Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Suchergebnisse filtern